Scott T. Tagawa, MD, MS, FACP, FASCO

“If there's enough radiation, then the cells can't repair themselves and die because of the radiation,” says Scott T. Tagawa, MD, MS, FACP, FASCO.

Scott T. Tagawa, MD, MS, FACP, FASCO, offers a comprehensive look at the evolving treatment landscape, with a focus on practical considerations and ongoing research.

An overview of the toxicity profile of enfortumab vedotin and pembrolizumab in patients being treated for urothelial carcinoma.

Dr. Tagawa offers his initial impressions on the second patient case and discusses data on enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma.

An expert on urothelial carcinoma reviews the case of a 76-year-old patient with advanced, resectable urothelial carcinoma.

Scott T. Tagawa, MD, MS, FACP, FASCO, a urothelial carcinoma specialist, discusses adverse events seen in patients receiving sacituzumab govitecan.

A medical oncologist specializing in urothelial carcinoma reviews key data on erdafitinib, enfortumab vedotin, and sacituzumab govitecan.

An expert on urothelial carcinoma gives an overview of disease risk factors, patient diagnosis, and testing practices.

Scott T. Tagawa, MD, MS, FACP, FASCO, presents the case of 72-year-old patient with metastatic urothelial carcinoma and offers his initial impressions.